Drug Trial Radar · NCT05505825
A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Aug 26, 2022
Primary completion
Jul 19, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- Collaborators
- Chipscreen Biosciences, Ltd.
- First posted
- Aug 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ib/II open label,international multicentre study to evaluate the efficacy and safety of anti-PD-1 and CTLA-4 bispecific antibody AK104 in combination with Chiauranib in Patients with Extensive Stage Small Cell Lung Cancer Who Failed First-line Platinum-based Chemotherapy in Combination with PD1/PDL1 Inhibitors
Conditions
- SCLC,Extensive Stage
Interventions
AK104 IV infusion;Chiauranib oralDrug
AK104 IV infusion once every 3 weeks;Chiauranib once a day oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to approximately 2 years
- Incidence and severity of adverse events(AEs)Time frame: Up to approximately 2 years
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Westmead Hospital
Westmead, New South Wales, Australia
Icon Cancer Centre
South Brisbane, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Sunshine Hospital
St Albans, Victoria, Australia
Jilin Province Cancer Hospital
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.